Opiant Pharmaceuticals (NASDAQ: OPNT) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Institutional and Insider Ownership

37.2% of Alimera Sciences shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by insiders. Comparatively, 14.7% of Alimera Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Opiant Pharmaceuticals and Alimera Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 38.89% 5,686.82% 87.49%
Alimera Sciences -68.58% N/A -36.39%

Risk & Volatility

Opiant Pharmaceuticals has a beta of -0.97, meaning that its stock price is 197% less volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Opiant Pharmaceuticals and Alimera Sciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Alimera Sciences 0 0 3 0 3.00

Alimera Sciences has a consensus price target of $4.00, indicating a potential upside of 191.97%. Given Alimera Sciences’ higher possible upside, analysts clearly believe Alimera Sciences is more favorable than Opiant Pharmaceuticals.

Earnings and Valuation

This table compares Opiant Pharmaceuticals and Alimera Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million 5.18 $5.99 million $2.54 15.06
Alimera Sciences $35.96 million 2.63 -$16.78 million ($0.39) -3.51

Opiant Pharmaceuticals has higher revenue, but lower earnings than Alimera Sciences. Alimera Sciences is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Opiant Pharmaceuticals beats Alimera Sciences on 7 of the 12 factors compared between the two stocks.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

About Alimera Sciences

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.